关于：卡介苗无反应性非肌层浸润性膀胱癌中的白细胞介素-15超激动剂NAI - Suppr | 超能文献

Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.

作者信息

Suderman Jonathan, St-Laurent Marie-Pier, Black Peter C

机构信息

Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

出版信息

Eur Urol. 2023 Jun;83(6):581. doi: 10.1016/j.eururo.2023.01.009. Epub 2023 Feb 1.

DOI:10.1016/j.eururo.2023.01.009

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.关于：卡介苗无反应性非肌层浸润性膀胱癌中的白细胞介素-15超激动剂NAI

Eur Urol. 2023 Jun;83(6):581. doi: 10.1016/j.eururo.2023.01.009. Epub 2023 Feb 1.

2

An Interleukin-15 Superagonist with BCG - A Major Therapeutic Advancement or Just a Small Step in the Right Direction?白细胞介素-15 超级激动剂联合卡介苗：重大治疗进展还是正确方向上的一小步？

NEJM Evid. 2023 Jan;2(1):EVIDe2200264. doi: 10.1056/EVIDe2200264. Epub 2022 Dec 27.

3

Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?卡介苗（BCG）无反应的非肌层浸润性膀胱癌：各亚组相同吗？

BJU Int. 2023 Oct;132(4):384-386. doi: 10.1111/bju.16087. Epub 2023 Jun 15.

4

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。

NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.

5

SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.SWOG S1605：超越卡介苗无反应性非肌层浸润性膀胱癌的全身免疫检查点抑制剂单一疗法

Eur Urol. 2023 Dec;84(6):545-546. doi: 10.1016/j.eururo.2023.09.013. Epub 2023 Oct 4.

6

ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.适应与即兴发挥：克服非肌层浸润性膀胱癌中卡介苗无反应性

Eur Urol. 2023 Jun;83(6):495-496. doi: 10.1016/j.eururo.2023.02.018. Epub 2023 Mar 9.

7

A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer.一种23基因预后指数可预测非肌层浸润性膀胱癌的进展及卡介苗反应。

Eur Urol. 2024 Apr;85(4):400-402. doi: 10.1016/j.eururo.2024.01.001. Epub 2024 Jan 11.

8

Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.预测临床病理因素以识别 T1 高分级非肌肉浸润性膀胱癌再次切除后对卡介苗无反应的患者。

Urol Oncol. 2022 Nov;40(11):490.e13-490.e20. doi: 10.1016/j.urolonc.2022.05.016. Epub 2022 Jun 5.

9

Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.2006-2018 年加利福尼亚州高分级非肌肉浸润性膀胱癌膀胱内化疗和免疫治疗的未充分利用：种族、年龄和社会经济地位对治疗差异的影响。

Urol Oncol. 2023 Oct;41(10):431.e7-431.e14. doi: 10.1016/j.urolonc.2023.05.019. Epub 2023 Jun 8.

10

Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC- 1901-BCG.高危非肌层浸润性膀胱癌患者年龄增加与卡介苗膀胱灌注反应降低的相关性：日本泌尿外科肿瘤学研究组JUOG-UC-1901-BCG的回顾性多机构研究结果

Urology. 2023 Mar;173:229. doi: 10.1016/j.urology.2022.10.031. Epub 2022 Dec 30.

引用本文的文献

1

Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.诺加彭德金α英巴奇普-pmln（安克蒂瓦）联合卡介苗：卡介苗无反应性非肌肉浸润性膀胱癌干预的有前景的武器。

Adv Pharm Bull. 2025 Mar 29;15(1):4-6. doi: 10.34172/apb.43870. eCollection 2025 Apr.

2

Review of BCG immunotherapy for bladder cancer.卡介苗免疫疗法治疗膀胱癌的综述。

Clin Microbiol Rev. 2025 Mar 13;38(1):e0019423. doi: 10.1128/cmr.00194-23. Epub 2025 Feb 11.